8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
What FDA Adverse Event Reporting System (FAERS) data show and do not show about Dayvigo (lemborexant) since its 2019 approval, including somnolence, sleep paralysis, complex sleep behaviors, and suicidal ideation reports, with the evidentiary limits of spontaneous-report data.
Dayvigo FDA label covers 5mg/10mg dosing, hepatic impairment caps, complex sleep behavior boxed warning, and driving impairment data from 2020-2026 revisions.
A detailed comparison of how the FDA and EMA evaluated and regulated Dayvigo (lemborexant), including approval timelines, label differences, scheduling, and post-market safety requirements.
A guide to Dayvigo (lemborexant) FDA approval status, compounding legal status, label warnings, and post-market safety data, with sourcing notes on what is established versus what needs verification.
A complete record of Dayvigo (lemborexant) FDA approval history, label changes, clinical trial data from SUNRISE-1 and SUNRISE-2, scheduling, and post-market safety updates.
A guide to lemborexant (Dayvigo) covering FDA approval history, patent disputes, label warnings, and post-market safety surveillance data.
Lemborexant (Dayvigo) is approved by the EMA plus FDA, Japan, Canada and Australia, with Schedule IV status and 5mg/10mg doses in the US.
Lemborexant (Dayvigo) is FDA-approved for insomnia; SUNRISE-3 data may support a new indication for dementia-related sleep-wake disorder. See current status.